Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture
JournalPhotochemistry and Photobiology
PublisherJohn Wiley & Sons
MetadataShow full item record
AbstractWe have demonstrated that lung-sparing surgery with intraoperative photodynamic therapy (PDT) achieves remarkably extended survival for patients with malignant pleural mesothelioma (MPM). Nevertheless, most patients treated using this approach experience local recurrence, so it is essential to identify ways to enhance tumor response. We previously reported that PDT transiently activates EGFR/STAT3 in lung and ovarian cancer cells and inhibiting EGFR via erlotinib can increase PDT sensitivity. Additionally, we have seen higher EGFR expression associating with worse outcomes after Photofrin-mediated PDT for MPM, and the extensive desmoplastic reaction associated with MPM influences tumor phenotype and therapeutic response. Since extracellular matrix (ECM) proteins accrued during stroma development can alter EGF signaling within tumors, we have characterized novel 3D models of MPM to determine their response to erlotinib combined with Photofrin-PDT. Our MPM cell lines formed a range of acinar phenotypes when grown on ECM gels, recapitulating the locally invasive phenotype of MPM in pleura and endothoracic fascia. Using these models, we confirmed that EGFR inhibition increases PDT cytotoxicity. Together with emerging evidence that EGFR inhibition may improve survival of lung cancer patients through immunologic and direct cell killing mechanisms, these results suggest erlotinib-enhanced PDT may significantly improve outcomes for MPM patients. © 2018 The American Society of Photobiology
SponsorsAcknowledgements: This work has been supported in part by NIH/NCI P01-CA087971 and the Penn Translational Centers for Excellence in Mesothelioma Research and Radiation Oncology.
KeywordErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride--therapteutic use
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85059621854&doi=10.1111%2fphp.13067&partnerID=40&md5=5992c12491c58562b06fde13d1e6d745; http://hdl.handle.net/10713/8635
- Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
- Authors: Kato T, Jin CS, Lee D, Ujiie H, Fujino K, Hu HP, Wada H, Wu L, Chen J, Weersink RA, Kanno H, Hatanaka Y, Hatanaka KC, Kaga K, Matsui Y, Matsuno Y, De Perrot M, Wilson BC, Zheng G, Yasufuku K
- Issue date: 2018 Nov
- Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma.
- Authors: Pass HI, Temeck BK, Kranda K, Thomas G, Russo A, Smith P, Friauf W, Steinberg SM
- Issue date: 1997 Dec
- Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma.
- Authors: Cavin S, Gkasti A, Faget J, Hao Y, Letovanec I, Reichenbach M, Gonzalez M, Krueger T, Dyson PJ, Meylan E, Perentes JY
- Issue date: 2020 Oct 1
- Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
- Authors: Jänne PA, Taffaro ML, Salgia R, Johnson BE
- Issue date: 2002 Sep 15
- Photodynamic therapy for lung cancer and malignant pleural mesothelioma.
- Authors: Simone CB 2nd, Cengel KA
- Issue date: 2014 Dec